

IRRITABLE BOWEL SYNDROME



Inflammatory bowel diseases (IBD), comprised of Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-mediated diseases of the gastrointestinal tract. IBD is characterized by symptoms of intense visceral pain, nausea, diarrhea, and subsequent weight loss. Due to the intermittent and sudden occurrence of symptoms, this condition can cause substantial physical and emotional stress.

Clinically, activation of the cannabinoid receptors is crucial to treating the inflammatory and pain states of IBS. It has been shown that cannabis administered through inhalation does not improve disease progression, but does show improvement in abdominal pain, abdominal cramping, joint pain, and decreased gut motility (diarrhea) symptoms.

The PPAR γ receptor (Peroxisome Proliferator-Activated Receptor) is a nuclear receptor highly expressed in the GI tract and functions through controlling gene expression and energy metabolism. Commercially approved PPAR γ agonists (Rosiglitazone and Pioglitazone) are known to treat Crohn's/UC in preclinical models, although clinical trials in IBS may be lacking due to their known side effects.

Some recent studies have shown a close interaction between the CB2 receptor and PPAR γ as well. Indeed, PPAR agonists ameliorate experimental colitis in animal models, and PPAR γ expression is reduced in patients with ulcerative colitis.

Cannabis and its components are known partial agonists of the PPAR receptors and may provide a benefit over commercial PPAR medicines through a reduced side effect profile.

Rick Simpson Oil (RSO) is a raw cannabis extract enriched in the acidic cannabinoid forms (THCA, CBDA) and has been shown to improve the symptoms and prognosis of IBD patients, although it hasn't been clinically studied. The effectiveness of THCA and CBDA point to PPAR γ as the main target, as the acid forms are significantly more potent at activating PPAR γ than the corresponding neutral forms.

Cannabidiol has been shown to improve inflammatory symptoms of UC in animal models as well. These effects were found to be dependent on PPAR γ activation.

TERPENES

BCP and humulene are known to improve colitis symptoms and systemic inflammation and should be prioritized over other terpenes.

Other terpenes that could provide relief are Myrcene, Terpinolene, and p-Cymene, all of which may help treat visceral pain due to their analgesic properties.

REFERENCES/BIBLIOGRAPHY

- Ambrose, T., and Simmons, A., "Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?" *J Crohns Colitis*. 13(2019), 525-535. <https://doi.org/10.1093/ecco-jcc/jjy185>
- Bento, A.F., Calixto, J.B., et al., "β-Caryophyllene Inhibits Dextran Sulfate Sodium-Induced Colitis in Mice through CB2 Receptor Activation and PPARγ Pathway." *Am J Pathol*. 178(2011), 1153-66. <https://doi.org/10.1016/j.ajpath.2010.11.052>
- Hasenoehrl, C., Storr, M., and Schicho, R., "Cannabinoids for Treating Inflammatory Bowel Diseases: Where are We and Where do We Go?" *Expert Review of Gastroenterology & Hepatology* 11(2017), 329-337. <https://doi.org/10.1080/17474124.2017.1292851>
- Ke, P., Shao, B.Z., et al., "Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages," *PLoS One*. 11(2016), e0155076. <https://doi.org/10.1371/journal.pone.0155076>
- Picardo, S., Sharkey, K.A., et al., "Insights into the Role of Cannabis in the Management of Inflammatory Bowel Disease," *T herap Adv Gastroenterol*. 12(2019), 1756284819870977. <https://doi.org/10.1177/1756284819870977>
- Roudsari, N.M., Abdolghaffari, A.H., et al., "PPARγ: A Turning Point for Irritable Bowel Syndrome Treatment," *Life Sciences* 257(2020), 118103. <https://doi.org/10.1016/j.lfs.2020.118103>
- Sánchez-Hidalgo, M., Martín, A.R., Villegas, I., de la Lastra, C.A., "Rosiglitazone, a PPARγ Ligand, Modulates Signal Transduction Pathways During the Development of Acute TNBS-Induced Colitis in Rats," *European Journal of Pharmacology* 562(2007), 247-258. <https://doi.org/10.1016/j.ejphar.2007.01.047>
- Sharkey, K., and Wiley, J., "The Role of the Endocannabinoid System in the Brain-Gut Axis," *Gastroenterology* 151(2016), 252-266. <https://doi.org/10.1053/j.gastro.2016.04.015>
- Takagi, T., Naito, Y., et al., "Pioglitazone, a PPAR-γ Ligand, Provides Protection from Dextran Sulfate Sodium-Induced Colitis in Mice in Association with Inhibition of the NF-κB-Cytokine Cascade," *Redox Report* 7(2002), 283-289. <https://doi.org/10.1179/135100002125000802>

All information provided by Bountiful Farms, Inc. is for informational and educational purposes only. These materials contain a compilation of publicly available information. This information, including information available by linking to third-party websites, is not intended to be and is not to be construed as medical advice and should not be used or relied upon in connection with the diagnosis, treatment, cure, or prevention of any disease, condition, or symptom and does not constitute a recommendation for such use. As always, please consult your personal health care provider before using any substance, including products derived from cannabis, for such purposes. Never disregard or delay medical advice based on this information. Bountiful Farms, Inc. (including its officers, directors, employees, and agents) is not liable for any information provided or with respect to recommendations related to the use of cannabis or products derived from cannabis for any health or other purposes. The products or claims about any referenced substances or products have not been evaluated by the Food and Drug Administration.

BOUNTIFUL FARMS

Bountiful Farms Inc. | 200 Kenneth Welch Drive Lakeville, MA 02347 | 774-419-3803 | bountifulfarms.care